AIM ImmunoTech Q3 2026 net loss narrows 6% to $3.1 million
AIM•AIM ImmunoTech’s third-quarter 2026 net loss narrowed 6% year over year to about $3.1 million, while cash, cash equivalents and marketable securities more than doubled to about $6.9 million. The company expects topline results from its Phase 2 DURIPANC study in Q1 2027.
1. Quarterly results
AIM ImmunoTech’s third-quarter 2026 net loss narrowed 6% year over year to approximately $3.1 million. Cash, cash equivalents and marketable securities totaled approximately $6.9 million at September 30, more than double the amount at December 31, 2025.
2. Research and clinical update
Research and development expenses rose 39% year over year to approximately $846,000, primarily reflecting Ampligen precursor manufacturing costs. Ampligen dosing in the Phase 2 DURIPANC study concluded, with topline pancreatic cancer results expected in Q1 2027 to inform pivotal Phase 3 development.
